GLP-1 ANALOG FUSION PROTEINS

• US 20090074769A1
• Filed: 10/31/2008
• Published: 03/19/2009
• Est. Priority Date: 06/12/2003
• Status: Active Grant

• Current Assignee: Andrew Mark Vick, Rohn Lee Jr. Millican, Wolfgang Glaesner
• Original Assignee: Andrew Mark Vick, Rohn Lee Jr. Millican, Wolfgang Glaesner
• Inventors: Vick, Andrew Mark, Millican, Rohn Lee JR., Glaesner, Wolfgang
• Granted Patent: US 8,273,854 B2
• Time in Patent Office: Days
• US Class Current: 424/134.100
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C07K 14/503 basic FGF [bFGF]
• CPC Class Codes: C07K 14/605 Glucagons
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.

Claims

1-25. -25. (canceled)

26. A method of treating a patient with non-insulin dependent diabetes mellitus comprising administering to the patient a therapeutically effective amount of a heterologous fusion protein comprising:

a GLP-1 analog comprising SEQ ID NO;

1

28. The method of claim 26 wherein the heterologous fusion protein is administered at a dose between about 0.01 mg/kg to 1 mg/kg body weight.

29. The method of claim 28 wherein the heterologous fusion protein is administered once a week.

27. A method of treating a patient with non-insulin dependent diabetes mellitus comprising administering to the patient a therapeutically effective amount of a heterologous fusion protein consisting of:

a GLP-1 analog consisting of SEQ ID NO;

1

30. The method of claim 27 wherein the heterologous fusion protein is administered at a dose between about 0.01 mg/kg to 1 mg/kg body weight.

31. The method of claim 30 wherein the heterologous fusion protein is administered once a week.